Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.

Image provided by Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Pasithea Therapeutics Corp. KTTA is a U.S.-based biotech company with the goal of researching and developing novel brain disorder treatments. Its subsidiary Pasithea Clinics offers ketamine-infusion therapy geared toward improving the symptoms of certain mental health disorders.

Pasithea Clinics has launched in major U.S. and U.K. cities, including London, New York City, Los Angeles, San Diego, and San Francisco, and reports that it is quickly gearing up to add new locations nationwide and internationally.

Mobile clinics may be becoming an increasingly recognized solution for making healthcare more affordable, accessible, and improving patient outcomes. Pasithea states that it is committed to this goal and dedicated to making treatments more accessible to all patients — especially those suffering from brain disorders.

Intravenous (IV) ketamine therapy is designed to treat the symptoms of various mental health disorders — especially treatment-resistant depression and post-traumatic stress disorder. Pasithea Clinics are meant to enable patients to receive ketamine therapy in the privacy and comfort of their own homes while still being under the care of experienced medical staff.

Ketamine is a drug approved by the U.S. Food and Drug Administration (FDA) first introduced to the medical community as an anesthetic more than 50 years ago. It has recently been repurposed for the treatment of psychiatric disorders using significantly lower doses than in anesthesia and has been gaining ground as a possible treatment for mental health disorders.

Reports have said that IV ketamine treatment is shown to have a rapid and sustained effect, and up to 70% of patients have had a clinical response.

“The need for more effective treatment options for patients with mental health disorders has never been greater,” said Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics. “Ketamine, when used at subanesthetic doses, has been shown to be highly effective in treating some psychiatric disorders. Still, we need to broaden access to this treatment to a larger patient population in a safe and convenient way.”

“With patient safety as our top priority, all ketamine treatments will be delivered by board-certified medical professionals,” Marques said. “This launch is an important stepping stone in expanding our international footprint in this space.”

Pasithea Clinics now operates across several major U.S. cities, including New York City, Los Angeles, San Diego, and San Francisco. Plus, the company also maintains locations across several London neighborhoods, including Marylebone, Holborn, and Knightsbridge, under a partnership with Zen HealthCare.

Pasithea also announced recent expansions of its mobile clinics into Florida and Nevada. The company plans to continue to introduce Pasithea Clinics across the U.S. as part of its effort to expand accessible healthcare and in line with its overall business strategy.

Pasithea is a biotechnology company joining the sphere with companies like Sage Therapeutics, Inc. SAGE, Gilead Sciences Inc. GILD, and FSD Pharma Inc. HUGE — albeit with a specialized focus on brain disorder treatments.

Learn more about Pasithea’s ongoing therapeutic solutions, latest developments and investor information on the company at pasithea.com.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content was purely for informational purposes only and not intended to be investing advice.